Agent Promising for Refractory Colon Cancer (CME/CE)
(MedPage Today) — The novel nucleoside drug TAS-102 may boost survival in refractory metastatic colorectal cancer, a phase II trial showed.
(MedPage Today) — The novel nucleoside drug TAS-102 may boost survival in refractory metastatic colorectal cancer, a phase II trial showed.

Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
 
 This site complies with the  HONcode standard for trustworthy health information: 
verify here.
 This site complies with the  HONcode standard for trustworthy health information: 
verify here. 
 
  


